Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesAn alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.Studies of retroviral infection in humanized miceImpacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivoImpaired antibody response causes persistence of prototypic T cell-contained virusAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Patterns of HIV/SIV Prevention and Control by Passive Antibody ImmunizationFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.The good and evil of complement activation in HIV-1 infectionComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionAnimal models for HIV/AIDS researchIdentification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesAffinity maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries.Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersHighly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Progress and challenges in therapies for AIDS in nonhuman primate models.Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virusIdentification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolateKinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroEffector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subjectPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
P2860
Q24561905-8EBD32BC-2995-454A-8CBA-A15A6AB1DFF6Q25256583-03B84979-60CB-4354-8B7C-B49573E44923Q26849806-800896D4-E571-4EA9-AB02-B92F9C48C47DQ26851152-1FC705F2-A729-4B46-B93A-858DDC4DFACEQ27331309-24D4D91B-24F7-4D3D-9036-076C49950FBDQ27469855-C32FBC6F-3739-45AE-8437-B3D9015CD350Q28068018-934B3986-9FAD-49C7-97D1-DD90FB7C6DB7Q28217208-4F8C1D99-C9E3-4191-9AC8-D7A33F98A264Q28275986-BA3F4D55-2B58-40CD-9FE2-C4AAF8B78998Q28766705-1E00C637-0FE6-433B-B573-7D0ADE2DDE9EQ30423656-C3611475-C146-4C19-94CE-DAF47FAA677EQ30701127-E3E69F3C-72D4-4043-A65A-538F08ECC511Q30923970-B92DA710-4420-439E-A8DA-9F2C6C614741Q30994182-3FA12F03-4781-4533-8234-919C2C574E19Q31148151-5DBE2AD4-A96C-4CF6-8AED-84EC42DDB10FQ33444658-687C6B5F-4441-41CB-8A62-B9946E65DF66Q33645828-8FA5DB2F-18A0-4B57-85D5-6883806D81FDQ33647300-0DAE29B1-DB80-4398-84FD-AFB2FB02EF52Q33781055-D8E8CBEB-2DC5-4340-8C78-BB1CBA5478F6Q33782556-FCEC651E-3F71-4E50-943B-9496890B3C95Q33783578-C62B7DC2-CD8A-4269-92F7-6127EF4A859EQ33786382-87A5B035-EF4B-4948-AD97-53C10FA7BE9DQ33792077-0FAC5F2A-C914-46EB-92A3-A4389B0ADBF1Q33800760-7C4BF375-F812-46C6-AE1E-FB5F95650004Q33809225-942D72C9-98C7-401A-B456-C5909AD7F1C9Q33811940-25EC0CBC-075C-48B4-A951-F70626DFEBB8Q33820285-18C4789B-8DCF-49A4-96CB-B5253FDB31FDQ33822395-A8242D33-67D8-4ED5-8FCD-3D5ECE74281FQ33835295-BB68A48A-620B-4A7B-AB84-4392FF5FC11AQ33842286-652680B4-C819-47E5-B377-EEE75EC504E7Q33850605-02D9D682-14A5-47C5-AF70-A034C7C53420Q33853775-0F5653E2-8485-46AB-8182-311E979ECBDCQ33870167-61B8AB07-CD1B-4420-BA9A-F2850A2AAF8CQ33870236-BA96E913-E369-4A59-A474-4516F7AC7E2FQ33910507-B5AD944F-97C7-42BA-96F9-A8D982281162Q34103170-3A72DBAB-0B47-4542-B0FC-2DA806368B72Q34142795-C5034A9F-C13C-4871-B298-0EF6F5F8E97AQ34150125-4BEEB91B-C5B7-4CEA-BF48-D3F438748BE5Q34326222-60273B32-72F5-471E-BFA2-3C606F755BDAQ34332284-923A2B01-3C6A-457C-BB53-AC6BBDA9D5F9
P2860
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Passive immunization with a hu ...... by primary isolates of HIV-1.
@en
Passive immunization with a hu ...... by primary isolates of HIV-1.
@nl
type
label
Passive immunization with a hu ...... by primary isolates of HIV-1.
@en
Passive immunization with a hu ...... by primary isolates of HIV-1.
@nl
prefLabel
Passive immunization with a hu ...... by primary isolates of HIV-1.
@en
Passive immunization with a hu ...... by primary isolates of HIV-1.
@nl
P2093
P2860
P356
P1433
P1476
Passive immunization with a hu ...... by primary isolates of HIV-1.
@en
P2093
P2860
P2888
P304
P356
10.1038/NM1297-1389
P407
P577
1997-12-01T00:00:00Z